Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2019–2020

Documentación CAPI
Influenza
Canadá
Título(s) original(es)
Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2019–2020
Autor(es)
NACI
Topics
recomendación
Fuente(s)
CAPI - Canadá
Año de publicación
2019

Descripción

The National Advisory Committee on Immunization (NACI) provides the Public Health Agency of Canada (hereafter referred to as PHAC) with ongoing and timely medical, scientific, and public health advice relating to immunization.
In addition to burden of disease and vaccine characteristics, the Public Health Agency of Canada has expanded the mandate of NACI to include the consideration of programmatic factors in developing evidence-based recommendations to facilitate timely decision-making for publicly funded vaccine programs at provincial and territorial levels.
The additional factors to be considered by NACI include: economics, ethics, equity, feasibility, and acceptability. Over the coming years NACI will be refining methodological approaches to include these factors. Not all NACI Statements will require in-depth analyses of all programmatic factors. As NACI works towards full implementation of the expanded mandate, select Statements will include varying degrees of programmatic analyses for public health programs.
PHAC acknowledges that the advice and recommendations set out in this statement are based upon the best current available scientific knowledge and is disseminating this document for information purposes. People administering the vaccine should also be aware of the contents of the relevant product monograph(s). Recommendations for use and other information set out herein may differ from that set out in the product monograph(s) of the Canadian manufacturer(s) of the vaccine(s). Manufacturer(s) have sought approval of the vaccine(s) and provided evidence as to its safety and efficacy only when it is used in accordance with the product monographs. NACI members and liaison members conduct themselves within the context of PHAC’s Policy on Conflict of Interest, including yearly declaration of potential conflict of interest.

Noticias y eventos relacionados

  • Canadá

    NACI mandate expands to support local decision-making on vaccine programs

    28.07.2017

    In June 2016 the Public Health Agency of Canada (PHAC) announced that the mandate of Canada’s NITAG, the National Advisory Committee on Immunization (NACI) will be expanded. In addition to the assessment of vaccine characteristics (safety, efficacy, effectiveness, and immunogenicity), NACI will also be assessing additional programmatic elements including economic evaluations, feasibility of implementation, acceptability, ethics and equity. 

    Leer más
  • Canadá

    Introducing NACI newest recommendations regarding the use of Hepatitis B vaccine

    29.03.2017

    NACI have released the update on the recommended use of Hepatitis B vaccine. It includes 4 main recommendations:

    1. NACI does not recommend routine booster doses of HB vaccine for immunocompetent individuals following the completion of a recommended HB immunization schedule given in infancy.
    2. NACI recommends that adults with diabetes need not be considered as a separate high risk group for immunization with HB vaccine.
    3. For immunocompromised individuals, initial annual monitoring of HB antibody levels following HB immunization may be considered
    4. Immunization with HB-containing vaccine should be provided according to determined provincial and territorial (P/T) schedules.
    Leer más
  • Chile
    Functionamiento

    Chile's NITAG documents the results of the committee's evaluation

    02.07.2019

    In this article, we describe the structure, functioning and work processes of Chile’s NITAG (CAVEI) and assess its functionality, quality of work processes and outputs, and integration of the committee into the Ministry of Health policy process using the Assessment tool for National Immunization Technical Advisory Groups.

    Leer más